The Latin America, Middle East and Africa Rare Diseases Treatment Market is expected to witness market growth of 16% CAGR during the forecast period (2022-2028).
Despite the fact that only a small percentage of patients are affected by specific rare diseases, the market for therapeutics for these conditions is expanding due to radical changes in regulatory frameworks and research and development. Payers and policymakers are thinking about making adjustments to meet the demands of this expanding market and any difficulties it might pose.
Such beneficial government initiatives may aid industry growth over the projected period. Furthermore, companies have launched initiatives like collaborations and partnerships to develop, manufacture, and commercialize products in the market. A large number of rare disease treatment providers are offering various advanced injectables in order to serve the patients better.
As being among the region's most economically developed and diverse markets, the UAE has a strong healthcare infrastructure. The UAE government has made developing a world-class healthcare infrastructure a top priority, and as a result, the sector has developed & grown significantly in recent years. The UAE government has moved quickly to put preventive health measures in place. The UAE's healthcare sector has grown to meet the changing needs of the country's population as well as the country's ambition to become a regional hub for medical tourism.
The Brazil market dominated the LAMEA Rare Diseases Treatment Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $4,855.7 million by 2028. The Argentina market is exhibiting a CAGR of 16.7% during (2022 - 2028). Additionally, The UAE market is poised to grow at a CAGR of 15.7% during (2022 - 2028).
Based on Distribution Channel, the market is segmented into Specialty Pharmacy, Hospital Pharmacy, and Online Pharmacy. Based on Route of Administration, the market is segmented into Injectable, Oral, and Others. Based on Therapeutic Area, the market is segmented into Cancer, Cardiovascular Conditions, Infectious Diseases, Musculoskeletal Conditions, Endocrine Disorders, Metabolic Disorders, Hematologic Disorders, Neurological Conditions, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Merck Group, Bristol Myers Squibb Company, Pfizer, Inc., AstraZeneca PLC, Takeda Pharmaceutical Company Limited and PTC Therapeutics, Inc.
Despite the fact that only a small percentage of patients are affected by specific rare diseases, the market for therapeutics for these conditions is expanding due to radical changes in regulatory frameworks and research and development. Payers and policymakers are thinking about making adjustments to meet the demands of this expanding market and any difficulties it might pose.
Such beneficial government initiatives may aid industry growth over the projected period. Furthermore, companies have launched initiatives like collaborations and partnerships to develop, manufacture, and commercialize products in the market. A large number of rare disease treatment providers are offering various advanced injectables in order to serve the patients better.
As being among the region's most economically developed and diverse markets, the UAE has a strong healthcare infrastructure. The UAE government has made developing a world-class healthcare infrastructure a top priority, and as a result, the sector has developed & grown significantly in recent years. The UAE government has moved quickly to put preventive health measures in place. The UAE's healthcare sector has grown to meet the changing needs of the country's population as well as the country's ambition to become a regional hub for medical tourism.
The Brazil market dominated the LAMEA Rare Diseases Treatment Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $4,855.7 million by 2028. The Argentina market is exhibiting a CAGR of 16.7% during (2022 - 2028). Additionally, The UAE market is poised to grow at a CAGR of 15.7% during (2022 - 2028).
Based on Distribution Channel, the market is segmented into Specialty Pharmacy, Hospital Pharmacy, and Online Pharmacy. Based on Route of Administration, the market is segmented into Injectable, Oral, and Others. Based on Therapeutic Area, the market is segmented into Cancer, Cardiovascular Conditions, Infectious Diseases, Musculoskeletal Conditions, Endocrine Disorders, Metabolic Disorders, Hematologic Disorders, Neurological Conditions, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Merck Group, Bristol Myers Squibb Company, Pfizer, Inc., AstraZeneca PLC, Takeda Pharmaceutical Company Limited and PTC Therapeutics, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Drug Type- Biologics
- Biosimilar
- Small Molecule
- Specialty Pharmacy
- Hospital Pharmacy
- Online Pharmacy
- Injectable
- Oral
- Others
- Cancer
- Cardiovascular Conditions
- Infectious Diseases
- Musculoskeletal Conditions
- Endocrine Disorders
- Metabolic Disorders
- Hematologic Disorders
- Neurological Conditions
- Others
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- AbbVie, Inc.
- F. Hoffmann-La Roche Ltd.
- Bayer AG
- Novartis AG
- Merck Group
- Bristol Myers Squibb Company
- Pfizer, Inc.
- AstraZeneca PLC
- Takeda Pharmaceutical Company Limited
- PTC Therapeutics, Inc.
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. LAMEA Rare Diseases Treatment Market by Drug Type
Chapter 5. LAMEA Rare Diseases Treatment Market by Distribution Channel
Chapter 6. LAMEA Rare Diseases Treatment Market by Route of Administration
Chapter 7. LAMEA Rare Diseases Treatment Market by Therapeutic Area
Chapter 8. LAMEA Rare Diseases Treatment Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- AbbVie, Inc.
- F. Hoffmann-La Roche Ltd.
- Bayer AG
- Novartis AG
- Merck Group
- Bristol Myers Squibb Company
- Pfizer, Inc.
- AstraZeneca PLC
- Takeda Pharmaceutical Company Limited
- PTC Therapeutics, Inc.
Methodology
LOADING...
